The modification signals continued government commitment to Regeneron's Ebola therapeutic franchise. Monitor for additional task orders or follow-on contracts under this IDIQ vehicle, as well as potential expansion into other biodefense or pandemic preparedness programs.
Price Chart
Executive Summary
Regeneron Pharmaceuticals received a $277.8 million government contract modification from HHS for INMAZEB Ebola therapeutics. This represents approximately 1.6% of annualized revenue, a notable but not transformative award that reinforces Regeneron's role as a key government partner for pandemic preparedness and biodefense.
Key Financial Metrics
Key Facts
- Contract modification P00018 to HHSO100201700016C valued at $277,818,931.33
- Awarding agency: Department of Health and Human Services
- Product: INMAZEB Ebola therapeutics
- Action date: 2026-09-25
- Award represents ~1.6% of Regeneron's annualized revenue of $17.164 billion
Financial Impact
$277.8 million contract modification, approximately 1.6% of annualized revenue
Risk Factors
- Government funding subject to continuing resolutions and appropriations risk
- INMAZEB revenue dependent on sporadic government stockpiling orders rather than recurring commercial demand
- Execution risk on manufacturing and delivery timelines
Investment Themes
Documents Analyzed
This report is based on 1 federal contract record from official U.S. government contract data.
| Document | Accession Number |
|---|---|
| GOVT-CONTRACT Data (Synthetic) | contract-HHSO100201700016C |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | Press Release | $807.67 | awaiting T+5 | — | $816.10 (+1.04%) |
Oct 25, 2026 2d ago | Press Release | $807.67 | awaiting T+5 | — | $816.10 (+1.04%) |
Oct 23, 2026 4d ago | Institutional Cluster | $805.02 | awaiting T+5 | — | $816.10 (−1.38%) |
Oct 15, 2026 12d ago | ANALYST-UPGRADE | $790.74 $805.02 | ▲ +1.81% | ▲ +2.24% | $816.10 (+3.21%) |
Oct 14, 2026 13d ago | 144 | $796.34 $819.09 | ▲ +2.86% | ▲ +3.87% | $816.10 (+2.48%) |
Oct 6, 2026 21d ago | 8-K | $738.72 $753.12 | ▲ +1.95% | ▲ +2.09% | $816.10 (+10.47%) |
Oct 1, 2026 26d ago | Press Release | $734.81 $739.57 | ▲ +0.65% | ▼ −0.65% | $816.10 (+11.06%) |
Oct 1, 2026 26d ago | Press Release | $734.81 $739.57 | ▲ +0.65% | ▼ −0.65% | $816.10 (+11.06%) |
Oct 1, 2026 26d ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Oct 1, 2026 26d ago | Press Release | $734.81 $739.57 | ▲ +0.65% | ▼ −0.65% | $816.10 (+11.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers